The process of retinal vascularization in retinopathy of prematurity after ranibizumab treatment in China

• 作者: Jian-Hong Liang Ming-Wei Zhao Qing-Yu Meng Yong Cheng
• 来源期刊: 国际眼科杂志:英文版
• 学科: 医学
• 关键词: RETINAL VASCULARIZATION RETINOPATHY of PREMATURITY RANIBIZUMAB AVASCULAR RETINAL area
• 年，卷（期）: 2019,（7）
• 页码范围: 1146-1150
• 页数: 5页
• 分类号: R

摘要

AIM: To explore the process of retinal vascularization and risk factors for retinopathy of prematurity (ROP) treated with intravitreal ran ibizumab (IVR) as mono therapy.METHODS: Infants with type 1 ROP who received IVR as primary treatment from August 2014 to October 2016 at Peking University People's HospitaPs Ophthalmology Department were included in the study. All eyes received 0.25 mg ranibizumab at initial treatment. Retinal vascularization was evaluated clinically. Potential risk factors were also recorded and examined.RESULTS: Retinal vascularization was completed in 126 eyes (62.7%), and retinal vascularization terminated in zone Ⅱ and zone Ⅲ with 16 eyes (7.9%) and 44 eyes (21.9%), respectively, after more than 1-year follow-up. In multivariate regression analysis, lower birth weight (BW), severity of ROP and repeated injections were found to be risk factors for peripheral avascular area (P<0.05).CONCLUSION: In our retrospective study, 29.8% of the ROP eyes treated with ranibizumab have peripheral avascular area at the last follow-up. Lighter BW and the severity of ROP are risk factors. Furthermore, repeated injections also increase the risk of retinal peripheral avascular area remaining in ROP patients.